# Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

> **NCT01652716** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 377 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Exenatide once weekly suspension
- **DRUG:** Exenatide twice daily

## Key facts

- **NCT ID:** NCT01652716
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2018-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01652716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01652716, "Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01652716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*